Status:

Red

Decision Date:

February 2022

Comments

RED: NICE TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis. (Decision date - July 2023)

 

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again